Trials / Conditions / Stevens-Johnson Syndrome

Stevens-Johnson Syndrome

24 registered clinical trials studyying Stevens-Johnson Syndrome — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NCT03585946	Massachusetts General Hospital	—
Not Yet Recruiting	Subconjunctival Humira for Boston Keratoprosthesis NCT06926478	Massachusetts Eye and Ear Infirmary	Phase 1
Not Yet Recruiting	Autologous Serum Obtained by a Closed-Circuit Collection Device NCT07014059	GIANCARLO FATOBENE	Phase 2
Completed	NATIENS: Optimal Management and Mechanisms of SJS/TEN NCT02987257	Vanderbilt University Medical Center	Phase 3
Unknown	Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. NCT05520086	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz	Phase 1 / Phase 2
Completed	Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN NCT06474078	Chang Gung Memorial Hospital	N/A
Unknown	Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necro NCT05145959	Massachusetts Eye and Ear Infirmary	N/A
Completed	Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study NCT06263140	Chulalongkorn University	—
Terminated	Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host NCT04313725	Tangible Science	N/A
Recruiting	Drug Reactions Sampling (COLLECTIONTOXIDERMIES) NCT03659227	Assistance Publique - Hôpitaux de Paris	—
Unknown	Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus NCT05284929	Sechenov University	—
Completed	G-CSF in the Treatment of Toxic Epidermal Necrolysis NCT02739295	University of Liege	Phase 4
Unknown	HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction NCT03046914	Seoul National University Hospital	N/A
Completed	Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantatio NCT02945176	Implandata Ophthalmic Products GmbH	N/A
Withdrawn	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis NCT02126020	James Chodosh, MD, MPH	Phase 1 / Phase 2
Available	Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation NCT02149732	Seoul National University Hospital	—
Completed	Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unres NCT01696500	Nihon Pharmaceutical Co., Ltd	Phase 3
Completed	Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis NCT01582880	Joseph B. Ciolino, MD	Phase 1 / Phase 2
Withdrawn	Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Tox NCT01256489	Massachusetts Eye and Ear Infirmary	Phase 1 / Phase 2
Terminated	Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis NCT02037347	Brett King	Phase 1 / Phase 2
Unknown	Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome Wi NCT01122303	Mahidol University	—
Completed	Stevens-Johnson Syndrome Antimicrobial NCT00844038	University of Pernambuco	—
Completed	Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye NCT01488396	Mahidol University	Phase 4
Completed	Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation NCT00346450	Singapore National Eye Centre	Phase 3